Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Curis Inc CRIS

Healthcare Biotechnology
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK... see more

Recent & Breaking News (NDAQ:CRIS)

Curis to Present at the RBC Capital Markets Global Healthcare Conference

GlobeNewswire February 19, 2014

Curis to Release Fourth Quarter and Year End 2013 Financial Results and Hold Conference Call on February 20, 2014

GlobeNewswire February 13, 2014

Curis to Present at the Leerink Global Healthcare Conference

Globe Newswire February 5, 2014

Curis Reports CUDC-907 Preliminary Data From the Ongoing Phase 1 Trial at ASH 2013 Annual Meeting

Globe Newswire December 9, 2013

Curis to Present at the Oppenheimer 24th Annual Healthcare Conference

Globe Newswire December 4, 2013

Curis to Present at Upcoming Investor Conferences

Globe Newswire November 26, 2013

TrendingWallStreet.com Reports Volume Analysis on SD, ENIP, AFFY, and CRIS

Accesswire November 7, 2013

Curis Reports Third Quarter 2013 Financial Results and Provides CUDC-427 Development Update

Globe Newswire November 6, 2013

Curis and Debiopharm Group(TM) Announce Initiation of Phase I Dose Finding Clinical Study with a Combination of HSP90 Inhibitor Debio 0932 and Everolimus (Afinitor®)

PR Newswire October 22, 2013

Curis and Debiopharm Group(TM) Announce Initiation of Phase I Dose Finding Clinical Study With a Combination of HSP90 Inhibitor Debio 0932 and Everolimus (Afinitor)(R)

Globe Newswire October 22, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on ARIA, CRIS, ECYT and IMGN

Accesswire October 1, 2013

Curis to Webcast Investor and Analyst Day in New York City

Globe Newswire September 26, 2013

Curis to Present at Upcoming Investor Conferences

Globe Newswire September 4, 2013

Curis Strengthens Leadership Team With Appointments of Jaye Viner, M.D. as Chief Medical Officer and Tania Chander, Pharm.D. as VP of Product Development

Globe Newswire August 13, 2013

Curis to Present at the 2013 Wedbush Life Sciences Management Access Conference

Globe Newswire August 7, 2013

Curis Reports Second Quarter 2013 Financial Results

Globe Newswire August 5, 2013

Curis to Release Second Quarter 2013 Financial Results and Hold Conference Call on August 5, 2013

Globe Newswire July 29, 2013

Curis Announces Initiation of a Clinical Trial of CUDC-427 In Advanced Malignancies

Globe Newswire July 25, 2013

Curis Announces the Conditional Approval of Erivedge(R) in the European Union

Globe Newswire July 15, 2013

Curis to Participate in Two Upcoming Investor Events

Globe Newswire July 3, 2013